Insider Selling: Edwards Lifesciences (NYSE:EW) VP Sells 1,019 Shares of Stock

Key Points

• Edwards VP Daniel Lippis sold 1,019 shares at an average price of $83.01 on May 1 for $84,587 under a pre-arranged Rule 10b5-1 plan, reducing his stake by 2.92% to 33,934 shares (about $2.82M).
• Edwards beat Q1 expectations with $0.78 EPS and $1.65B revenue, set FY2026 guidance of $2.95–3.05 EPS, and the stock carries a consensus "Moderate Buy" rating with an average target of $95.65.

Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) VP Daniel Lippis sold 1,019 shares of the stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $83.01, for a total value of $84,587.19. Following the completion of the sale, the vice president owned 33,934 shares of the company's stock, valued at approximately $2,816,861.34. This trade represents a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Stock Down 0.8%

Edwards Lifesciences stock traded down $0.66 during midday trading on Monday, reaching $83.32. The company's stock had a trading volume of 3,302,606 shares, compared to its average volume of 5,757,119. The stock's 50-day simple moving average is $82.08 and its 200-day simple moving average is $82.54. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $87.89. The stock has a market capitalization of $48.04 billion, a P/E ratio of 44.32, a PEG ratio of 2.11 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.17% and a net margin of 17.39%.The company had revenue of $1.65 billion during the quarter, compared to analysts' expectations of $1.60 billion. During the same period last year, the business posted $0.64 earnings per share. The firm's revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, sell-side analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on EW shares. Canaccord Genuity Group set a $85.00 price target on Edwards Lifesciences and gave the company a "hold" rating in a research note on Friday, April 24th. Mizuho set a $95.00 price objective on Edwards Lifesciences and gave the stock an "outperform" rating in a research note on Monday, April 13th. Piper Sandler restated an "overweight" rating and issued a $100.00 price objective (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. UBS Group restated a "neutral" rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Finally, Barclays restated an "overweight" rating and issued a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $95.65.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of EW. Brighton Jones LLC purchased a new position in shares of Edwards Lifesciences in the fourth quarter worth about $266,000. NewEdge Advisors LLC raised its position in Edwards Lifesciences by 8.1% during the second quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company's stock valued at $2,787,000 after acquiring an additional 2,665 shares in the last quarter. Sei Investments Co. raised its position in Edwards Lifesciences by 16.7% during the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company's stock valued at $32,285,000 after acquiring an additional 58,988 shares in the last quarter. Squarepoint Ops LLC raised its position in Edwards Lifesciences by 277.7% during the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company's stock valued at $5,417,000 after acquiring an additional 50,924 shares in the last quarter. Finally, Treasurer of the State of North Carolina raised its position in Edwards Lifesciences by 0.4% during the second quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company's stock valued at $21,028,000 after acquiring an additional 1,065 shares in the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.